JP2022551969A5 - - Google Patents
Info
- Publication number
- JP2022551969A5 JP2022551969A5 JP2022522657A JP2022522657A JP2022551969A5 JP 2022551969 A5 JP2022551969 A5 JP 2022551969A5 JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022551969 A5 JP2022551969 A5 JP 2022551969A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- nos
- cdr2
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915123P | 2019-10-15 | 2019-10-15 | |
| US62/915,123 | 2019-10-15 | ||
| PCT/US2020/055497 WO2021076564A1 (en) | 2019-10-15 | 2020-10-14 | Proteins binding nkg2d, cd16 and flt3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551969A JP2022551969A (ja) | 2022-12-14 |
| JP2022551969A5 true JP2022551969A5 (https=) | 2023-10-19 |
Family
ID=75538862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522657A Pending JP2022551969A (ja) | 2019-10-15 | 2020-10-14 | Ｎｋｇ２ｄ、ｃｄ１６およびｆｌｔ３に結合するタンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240117054A1 (https=) |
| EP (1) | EP4045538A4 (https=) |
| JP (1) | JP2022551969A (https=) |
| KR (1) | KR20220083770A (https=) |
| CN (1) | CN115298217A (https=) |
| AR (1) | AR120223A1 (https=) |
| AU (1) | AU2020368163A1 (https=) |
| BR (1) | BR112022007128A2 (https=) |
| CA (1) | CA3153858A1 (https=) |
| CL (2) | CL2022000928A1 (https=) |
| CO (1) | CO2022004757A2 (https=) |
| IL (1) | IL292261A (https=) |
| MX (1) | MX2022004430A (https=) |
| PE (1) | PE20221316A1 (https=) |
| TW (1) | TW202128759A (https=) |
| WO (1) | WO2021076564A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| US20240391971A1 (en) * | 2021-08-24 | 2024-11-28 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| AR127162A1 (es) * | 2021-09-29 | 2023-12-27 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y baff-r |
| WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| WO2017011803A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| US20200165344A1 (en) * | 2017-07-31 | 2020-05-28 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and flt3 |
| US20200231679A1 (en) * | 2017-08-23 | 2020-07-23 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| EA202090718A1 (ru) * | 2017-09-14 | 2020-07-01 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
| BR112020015994A2 (pt) * | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| BR112020016944A2 (pt) * | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos |
| EP3773676A4 (en) * | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
-
2020
- 2020-10-14 PE PE2022000621A patent/PE20221316A1/es unknown
- 2020-10-14 KR KR1020227016160A patent/KR20220083770A/ko active Pending
- 2020-10-14 AU AU2020368163A patent/AU2020368163A1/en active Pending
- 2020-10-14 JP JP2022522657A patent/JP2022551969A/ja active Pending
- 2020-10-14 US US17/769,160 patent/US20240117054A1/en active Pending
- 2020-10-14 AR ARP200102840A patent/AR120223A1/es unknown
- 2020-10-14 EP EP20876627.9A patent/EP4045538A4/en active Pending
- 2020-10-14 BR BR112022007128A patent/BR112022007128A2/pt unknown
- 2020-10-14 MX MX2022004430A patent/MX2022004430A/es unknown
- 2020-10-14 WO PCT/US2020/055497 patent/WO2021076564A1/en not_active Ceased
- 2020-10-14 CN CN202080072319.9A patent/CN115298217A/zh active Pending
- 2020-10-14 TW TW109135528A patent/TW202128759A/zh unknown
- 2020-10-14 CA CA3153858A patent/CA3153858A1/en active Pending
-
2022
- 2022-04-12 CL CL2022000928A patent/CL2022000928A1/es unknown
- 2022-04-13 IL IL292261A patent/IL292261A/en unknown
- 2022-04-13 CO CONC2022/0004757A patent/CO2022004757A2/es unknown
-
2024
- 2024-12-17 CL CL2024003895A patent/CL2024003895A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551969A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098732A5 (https=) | ||
| JP2021098733A5 (https=) | ||
| JP2021533169A5 (https=) | ||
| JP2023052214A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP2021512630A5 (https=) | ||
| JP2024537779A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2023106433A5 (https=) | ||
| CN102448985B (zh) | 三或四特异性抗体 | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2023538945A5 (https=) | ||
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2018537966A5 (https=) | ||
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2023532129A5 (https=) | ||
| IL311617A (en) | NKG2D, CD16 and BAFF-R binding proteins | |
| JP2021094022A5 (https=) | ||
| JP2023516004A5 (https=) | ||
| JP2021507698A5 (https=) | ||
| JP2024534545A5 (https=) |